Appoints Slava Akmaev, Ph.D., as Chief Technology Officer
Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed most effective therapy, today announces the addition of Slava Akmaev, Ph.D. as Chief Technology Officer to the growing leadership team. As CTO, Dr. Akmaev will oversee the data science and technology teams, ensuring efficient data on-boarding, quality control and rapid analytics to enhance Scipher’s pipeline of precision diagnostics.
"Having committed and talented individuals such as Slava on our team will help propel us towards our mission of improving patient outcomes and usher in a new era of precision medicine, one capable of providing better solutions for complex diseases," said Alif Saleh, Chief Executive Officer of Scipher Medicine.
Dr. Akmaev is a leader in applying high-throughput molecular technology, machine learning, artificial intelligence and data analysis within the life sciences and healthcare industry. Prior to joining Scipher, he was the Senior Vice President and Chief Analytics Officer at BERG, where he co-founded and led BERG Analytics; he previously commercialized four molecular diagnostic tests at Genzyme Genetrics. Dr. Akmaev routinely publishes peer-reviewed articles in journals such as Nature Biotechnology, the Journal of Computational Biology, Artificial Intelligence in Medicine and the Journal of Molecular Diagnostics.
"The path Scipher is taking to personalize medicine in a way that puts the molecular biology of each patient at the center of the treatment decision is something I have wanted to do for more than a decade," said Akmaev. "I’m thrilled to join this rapidly growing team that is tackling one of the most critical challenges in healthcare today by using precision medicine to optimize treatment for patients by leveraging its network medicine approach developed over the past decade."
For more information about Scipher Medicine, please visit ScipherMedicine.com
About Scipher Medicine
Scipher Medicine holds the fundamental belief that patients deserve simple answers to their treatment options using scientifically backed data. With artificial intelligence and its proprietary molecular technology platform, Scipher Medicine develops innovative diagnostic tests that predict which drug will work from day one and use the data from these tests to develop more effective therapies to improve patient outcomes.
Scipher Medicine is privately held, headquartered in Waltham, Massachusetts and backed by Khosla Ventures, Northpond Ventures and UnitedHealth Group. To learn more, visit ScipherMedicine.com and follow Scipher on Twitter and LinkedIn.